News & Updates
Filter by Specialty:
Hodgkin lymphoma incidence rising in Asia, HK tops global rise in males
The incidence of Hodgkin lymphoma has increased in the past decade, especially in Asian countries, females, and the younger population, a global study has shown.
Hodgkin lymphoma incidence rising in Asia, HK tops global rise in males
08 Jun 2022Does IBS elevate long-term risk of cancer?
People with irritable bowel syndrome (IBS) are not at increased overall risk of cancer relative to the general population, reveals a study. On the contrary, those with IBS appear to have a lower risk of incident colorectal cancer (CRC) and cancer-specific mortality.
Does IBS elevate long-term risk of cancer?
07 Jun 2022H. pylori eradication suppresses long-term gastric cancer risk
Helicobacter pylori eradication treatment leads to large reductions in the risk of gastric cancer and lower rates of associated deaths over 10 years of follow-up, according to a recent meta-analysis.
H. pylori eradication suppresses long-term gastric cancer risk
07 Jun 2022Transvaginal sonography accepted by women with PMB if high endometrial Ca detection rate
A recent cross-sectional questionnaire study has shown that women with postmenopausal bleeding (PMB) would select transvaginal sonography to measure endometrial thickness (TVS-ET) over gold-standard hysteroscopy with biopsy if TVS-ET achieved a median endometrial cancer detection rate of 95.0 percent.
Transvaginal sonography accepted by women with PMB if high endometrial Ca detection rate
07 Jun 2022Iatrogenic tumour seeding not a risk factor for metachronous CRC
In patients with colorectal cancer (CRC), biopsy of nontumour sites after biopsy of the primary cancer is unlikely to cause metachronous cancers, a study reports.
Iatrogenic tumour seeding not a risk factor for metachronous CRC
06 Jun 2022Elacestrant ups PFS vs SoC ET in ER-positive, HER2-negative advanced breast cancer
Elacestrant, a novel oral selective oestrogen receptor (ER) degrader, significantly improves progression-free survival (PFS) vs standard-of-care (SoC) endocrine therapy (ET) in patients with ER-positive, HER2-negative advanced breast cancer whose disease progressed after 1–2 prior lines of ET and a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, results of the phase III EMERALD trial have shown.